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SUMMARY
Alpha-1 adrenergic receptors (a1-ARs) play adaptive and protective roles in the heart. Dabuzalgron is an oral selective a1A-AR agonist that was well tolerated in multiple clinical trials of treatment for urinary incontinence, but has never been used to treat heart disease in humans or animal models. In this study, the authors administered dabuzalgron to mice treated with doxorubicin (DOX), a widely used chemotherapeutic agent with dose-limiting cardiotoxicity that can lead to heart failure (HF). Dabuzalgron protected against DOX- (reviewed in O'Connell et al. [1] ). There are 3 a1-AR subtypes: a1A, a1B, and a1D. In rodent and human myocardium, the a1A and a1B predominate, and there is no measurable a1D. The a1D is the major a1-AR subtype in human and mouse coronary arteries, where its activation promotes vasoconstriction (2, 3) . The role of the myocardial a1B remains unclear, but multiple lines of evidence suggest that the cardioprotective effects of nonselective a1-AR agonists are mediated by the a1A. Mice overexpressing the a1A have increased contractility (4) and are protected from ischemia-reperfusion injury (5), myocardial infarction (6, 7) , and transverse aortic constriction (8) . Abrogation of these adaptive processes may also account for the 2-fold increase in incident heart failure (HF) in hypertensive patients treated with the non-selective a1-AR antagonist, doxazosin, in ALLHAT (Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial) (9) . These findings and other evidence from animal and human studies suggest that activating myocardial a1A-ARs could be therapeutically effective in HF.
In this study, we used the oral selective a1A agonist We chose to test the therapeutic efficacy of dabuzalgron in preventing heart injury using an anthracycline cardiotoxicity model, given previous evidence demonstrating a1A-mediated cytoprotection after doxorubicin (DOX) treatment (12) (13) (14) . Anthracyclines, including DOX, are highly effective and commonly Beak et al.
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are central to the pathogenesis (reviewed in Tokarska-Schlattner et al. [17] ).
Here, we show that dabuzalgron protects against the cardiotoxic effects of DOX in vitro and in vivo by activating the a1A-AR, and we demonstrate that preservation of mitochondrial function is one novel mechanism underlying this benefit.
METHODS
Dabuzalgron was synthesized by Angene (Hong Kong)
per published chemical structure (18) , and its purity and identity were confirmed. Mice were 8-to 12-week- Figure 1A) .
To test the effect of an a1A agonist on cardiac hypertrophy, we administered dabuzalgron (1 to 100 mg/kg/day) or vehicle by gavage twice daily for 7 days. There was no measurable change in body weight or heart weight at any dose ( Table 1) , and no difference in heart weight indexed to tibia length could be found when comparing WT mice treated with dabuzalgron and water ( Figure 1B) . We used qRT-PCR to assay traditionally accepted molecular markers of hypertrophy in the hearts of mice treated with dabuzalgron. There was no change in the transcript abundance of atrial natriuretic peptide, beta myosin heavy chain, or alpha-skeletal actin ( Figure 1C ).
Collectively, these findings suggest that the chosen doses of dabuzalgron do not increase vascular tone or promote cardiac hypertrophy, 2 properties attributed to nonselective a1-AR activation.
DABUZALGRON PROTECTS AGAINST DOX CARDIOTOXICITY
BY ACTIVATING THE a1A-AR. To test whether therapeutic activation of the a1A could prevent DOX-induced cardiac injury, we treated WT mice and mice lacking the a1A (AKO mice) with DOX 20 mg/kg IP injection followed by 7 days gavage with either water or dabuzalgron 10 mg/kg twice daily ( Figure 2A ). There was no difference in baseline heart weight in WT and AKO mice ( Table 2 ). All animals treated with DOX lost 10% to 15%
of their body weight. Raw heart weight and heart weight indexed to tibia length were lower in mice treated with DOX than in vehicle-treated WT and AKO controls ( and unaffected by dabuzalgron administration ( Table 2) .
Previous studies in rodents (20) and humans (21) have demonstrated that a1-AR activation increases inotropy in failing heart tissue, though it has minimal effects on contractility of the uninjured heart.
Conscious echocardiography on Day 7 after DOX treatment in WT mice revealed a decrease in contractile function that was prevented by administration of dabuzalgron ( Figure 2B , Table 3 ). Fractional shortening and left ventricular end-systolic volume both were preserved in animals that received dabuzalgron after DOX ( Table 3) , though dabuzalgron had no effect on echocardiographic parameters in uninjured mice (data not shown). dabuzalgron. An omnibus test of transcript abundance across all groups was performed using DESeq2 with groups encoded as categorical variables. One hundred one genes were identified as significant by meeting the q < 0.05 threshold (the set of genes with a 5% false discovery rate) (Supplemental Table 1 ).
Gene set analysis was performed based on the univariate statistics calculated from DESeq2
(Supplemental Tables 2 and 3 ). Marked differences were identified in numerous pathways related to mitochondrial function ( Figure 3A ).
Further analysis of transcripts within these mitochondrial pathways revealed that DOX decreased the WT ¼ wild-type.
Beak et al. NRVMs express the a1A and a1B subtypes, have been used extensively to assess the effects of non-selective a1-AR activation, and faithfully predict in vivo a1-AR biology (25, 26) . To test the effect of an a1A agonist on 
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Beak et al. NRVMs were treated for 4 h with doxorubicin 2mM in the presence and absence of dabuzalgron 10 mmol/l. Apoptosis was detected using fluorescein isothiocyanate-labeled Annexin V, cell death was detected using propidium iodide (PI), and nuclei were labeled with Hoechst. 
Concomitant treatment with dabuzalgron abrogated

DISCUSSION
The central novel finding of this study is that the oral selective a1A-AR agonist, dabuzalgron, is protective against anthracycline-induced cardiotoxicity. Though dabuzalgron has not been tested previously in animal models of heart injury, it was well tolerated in 2 large randomized clinical trials for treatment of urinary incontinence. We found that its cardioprotective effect is mediated in part through preservation of mitochondrial function, an adaptive mechanism that has not been attributed previously to activation of cardiac a1A-ARs. a1-ARs are best known as vascular receptors, where a1-AR activation promotes vasoconstriction. At high doses, nonselective a1-AR agonists such as phenylephrine increase BP experimentally and clinically. In this study, we found no effect on BP or HR in mice treated with a range of dabuzalgron doses. We chose to use 10 mg/kg for subsequent experiments because Roche studied this dose in pigs and rabbits (10) . Our findings mirror the published human experience with dabuzalgron as a treatment for urinary incontinence, wherein administration of 1.5 mg by mouth twice daily did not alter BP or HR (11) .
Though cardiac a1-ARs are a minor AR subpopulation relative to b1-ARs, they contribute to numerous important processes in the heart (26) . Subpressor doses of nonselective a1-AR agonist also can cause cardiac hypertrophy, indicating a direct and load-independent effect on the heart (30). We found that activation of the a1A did not cause myocardial hypertrophy, consistent with the fact that heart size is normal in mice with global and cardiac-specific a1A overexpression (4-6). a1AKO mice on a congenic C57Bl6 background also have normal heart size and BP (data not shown). Mice lacking both myocardial a1 subtypes (a1ABKO) have small hearts (31) . Collectively, these findings suggest the a1B subtype mediates cardiomyocyte hypertrophy induced by non-selective a1-AR agonists.
We found that oral administration of a subpressor dose of dabuzalgron protected WT mice against DOX cardiotoxicity. This beneficial effect was absent in AKO mice, indicating that dabuzalgron's adaptive effects result from on-target activation of the a1A. High mortality and very poor contractile function in DOX-treated AKO mice further reinforce the cardioprotective function of the a1A-AR. Though other labs have used transgenic overexpression of the a1A to identify cardioprotective effects, ours is the first study to our knowledge to demonstrate greater susceptibility to cardiac injury in AKO mice. As such, we present evidence supporting adaptive functions for cardiac a1A-ARs using both novel pharmacological gain-of-function and novel genetic loss-of-function approaches.
The function of a1-ARs in cardiomyocyte mitochondria has not been explored to any significant extent previously. In our study, dabuzalgron protected against DOX-induced apoptosis and necrosis in NRVMs and decreased levels of intrinsic apoptotic effectors, suggesting that this benefit may be associated with
Beak et al. opathy is the most significant source of DOXassociated cardiac morbidity; however, numerous studies indicate that acute DOX cardiotoxicity is more common than previously thought (11% [37] to 21% [38] ) and predicts poor outcomes. In one recent study, 32% of subjects had elevated troponin I (TnI) acutely after DOX. Ejection fraction dropped measurably in most subjects by 3 months and early þTnI predicted durable reduction in ejection fraction (39) . In a followup study, the authors found that early institution of evidence-based HF therapy protected against chronic anthracycline cardiomyopathy (40). Collectively, these findings suggest that acute DOX cardiotoxicity may be a clinically meaningful and actionable entity.
We have proposed previously that a1-AR agonists could be used to treat HF (25) . 
CONCLUSIONS
Future mechanistic work will examine the role of the a1A-AR in regulating mitochondrial function and cellular energy production. We also plan to test selective a1A-AR activation with dabuzalgron in other mouse models of HF. These studies will help to determine the therapeutic potential of repurposing this well-tolerated oral a1A-AR agonist for the treatment of HF. Beak et al.
